Table 3 Disease-specific survival according to clinicopathological factors
From: High expression of p62/SQSTM1 predicts shorter survival for patients with pancreatic cancer
Variable | Cases | Deaths | Median survival (months) | 95% CI | Log-rank test (p) |
|---|---|---|---|---|---|
Age (years) | |||||
<65 years | 17 | 14 | 22.6 | 14.9–30.2 | |
≥65 years | 8 | 8 | 17.3 | 0.0–35.0 | 0.308 |
Sex | |||||
Female | 13 | 11 | 17.3 | 3.5–31.1 | |
Male | 12 | 11 | 23.2 | 16.5–29.8 | 0.524 |
Tumor location | |||||
Head | 22 | 20 | 22.1 | 15.6–28.7 | |
Others | 3 | 2 | 7.0 | 0.1–14.1 | 0.622 |
Tumor stage | |||||
pT1–2 | 13 | 11 | 22.6 | 15.6–29.5 | |
pT3–4 | 12 | 11 | 19.9 | 0.0–46.2 | 0.586 |
Differentiation | |||||
Medium or high | 16 | 14 | 19.9 | 10.8–29.0 | |
Low | 7 | 6 | 6.6 | 0.0–16.3 | 0.689 |
Lymph node metastasis | |||||
N0 | 9 | 8 | 23.2 | 0.0–70.3 | |
N1 | 16 | 14 | 19.9 | 10.8–29.0 | 0.847 |
Adjuvant chemotherapy | |||||
No | 18 | 17 | 17.3 | 0.0–38.7 | |
Yes | 7 | 5 | 44.9 | 30.4–59.4 | 0.092 |